Clinical Trials Logo

Filter by:
NCT ID: NCT04205786 Suspended - Clinical trials for HR-positive Breast Cancer

Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer

Start date: August 12, 2021
Phase: N/A
Study type: Interventional

Treatment of hormone receptor (HR)-positive breast cancer with Aromatase Inhibitors (AIs) can lead to associated musculoskeletal pain and may cause patients to discontinue important treatment. This is a randomized controlled trial assessing the affect of Vitamin B12 on AI-associated joint pain and other outcomes. Participants will be randomly assigned 1:1 to treatment or control arm. The primary objective of this study is: -To assess whether daily oral Vitamin B12 decreases average joint pain in women with AI-Associated Musculoskeletal Symptoms Secondary objectives include: - To investigate whether daily vitamin B12 improves functional quality of life - To explore the impact of treatment on serum inflammatory cytokine levels (C- reactive protein) between baseline and various points in treatment.

NCT ID: NCT04205734 Suspended - IBD Clinical Trials

Methotrexate Polyglutamate Measurements in Patients With Inflammatory Bowel Disease

Start date: January 30, 2021
Phase:
Study type: Observational

There are currently no serum levels to help guide appropriate methotrexate therapy. Data from this study will assess the correlation between dosing and whole blood methotrexate(MTX) polyglutamate measurements in children and adolescents with IBD.

NCT ID: NCT04202783 Suspended - Neuralgia Clinical Trials

The Use of Exosomes In Craniofacial Neuralgia

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and efficacy of exosome deployment in patients with Craniofacial Neuralgia. Secondarily, this study is designed to rigorously evaluate for any adverse events that may be related to the administration and reception of exosomes.

NCT ID: NCT04202770 Suspended - Anxiety Disorders Clinical Trials

Focused Ultrasound and Exosomes to Treat Depression, Anxiety, and Dementias

Start date: December 1, 2019
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and efficacy of exosome deployment with concurrent transcranial ultrasound in patients with refractory, treatment resistant depression, anxiety, and neurodegenerative dementia.

NCT ID: NCT04198753 Suspended - Clinical trials for Food Allergy in Children

Skin Characteristics of Parents of Food Allergic Pediatric Patients

Start date: January 23, 2020
Phase:
Study type: Observational

The purpose of this study is to determine whether disruptions in the skin barrier of parents can contribute to the development of food allergies in their offspring. The study team will compare the superficial skin layers of mothers and fathers who do not have children with diagnosed food allergies to the skin layers of parents who do have children with diagnosed food allergy. The study will include a questionnaire, noninvasive superficial skin testing with skin tapping and transepidermal water loss measurements, and a blood draw.

NCT ID: NCT04197102 Suspended - Clinical trials for Post Traumatic Stress Disorder

Use of CBD Oil in the Treatment of Posttraumatic Stress Disorder

Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

The overarching objective of the proposed project is to test the clinical efficacy of CBD in the treatment of post-traumatic stress disorder using a rigorous double-blind randomized clinical trial methodology. Participants (n=150) meeting full DSM-5 criteria for post-traumatic stress disorder (PTSD) will be randomized to one of 3 treatment arms: (a) CBD -Isolate; (b) CBD-Broad Spectrum; (c) Placebo oil. We predict that patients receiving CBD isolate or CBD Broad Spectrum will show significantly greater improvements in PTSD symptoms and functional impairment at the posttreatment and one-month follow-up relative to patients receiving placebo oil. Additionally, we expect that patients receiving CBD Broad Spectrum will show significantly greater improvements relative to patients receiving CBD Isolate.

NCT ID: NCT04193891 Suspended - Epilepsy Clinical Trials

The Effect of Ketogenic Dietary Therapy on Sleep in Adult Epilepsy

Start date: February 12, 2020
Phase:
Study type: Observational

The modified Atkins diet, a form of ketogenic therapy in which individuals severely restrict their carbohydrate intake and subsequently enter ketosis, has begun to be used as an adjunctive treatment in adults with intractable epilepsy who are not surgical candidates. In this study, the investigators examine the effect of ketogenic dietary therapy on sleep, as sleep deprivation is one of the most common seizure triggers and seizures themselves have been found to affect sleep quality. This pilot study will enroll twenty participants, ten of whom are initiating ketogenic dietary therapy and ten participants who are being treated with standard anti-seizure drug therapy.

NCT ID: NCT04190875 Suspended - Premature Infants Clinical Trials

Post-Discharge Growth and Development of Infants Who Received Targeted Fortification in the NICU

Start date: February 20, 2019
Phase:
Study type: Observational

Extremely low birth weight (ELBW) infants are at risk for slow growth, metabolic abnormalities, and poor neurodevelopmental outcomes. Postnatal growth standards are based on estimated intrauterine growth from historical cohort studies and post-mortem analyses. Despite current strategies aimed at appropriate nutrition, a large proportion of these infants have postnatal growth failure (anthropometric values < 10th percentile) reported in the literature as high as 89-99%. More recent data shows lower rates of postnatal growth failure but further improvement is still needed. Adequate growth is key to ensuring improved neurodevelopment and other outcomes. The investigators are currently evaluating the effects of a high versus standard protein enteral diet on growth and body composition in infants less than or equal to 1000 grams birth weight in the Neonatal Intensive Care Unit. (H-38611). Infants less than or equal to 1000 grams birth weight are provided an enteral diet with a level of protein based on individual caloric and protein analysis of human milk also known as targeted fortification. The standard protein diet provides 3.5-3.8 g/kg/day of protein, while the high protein diet provides 4.2-4.5 g/kg/day. The investigators have shown that infants who receive this diet achieve growth at targeted standards. As this diet is well tolerated and associated with improved outcomes in our highest risk neonates, it is imperative to evaluate the benefits of a high protein exclusive human milk diet and the possible positive changes in body composition, specifically lean mass, in these infants. Body composition in these infants receiving targeted fortification is being evaluated at 35-36 weeks post menstrual age. Because these infants are at such high risk for poor growth and neurodevelopment, it is important to investigate the impact of a higher protein exclusive human milk diet on long-term neurodevelopmental outcomes, body composition, and growth at 18-24 months.

NCT ID: NCT04185428 Suspended - Clinical trials for Acute Myeloid Leukemia

Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia

Start date: March 3, 2020
Phase: N/A
Study type: Interventional

This pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of Integrative Therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement, relaxation techniques, and massage therapy) as non-pharmacologic treatment for symptom management in newly diagnosed adult Acute Myeloid Leukemia (AML) patients undergoing induction chemotherapy

NCT ID: NCT04166552 Suspended - Clinical trials for Diffuse Cutaneous Systemic Sclerosis

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis

Start date: June 11, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of EHP-101 in adult subjects with diffuse cutaneous Systemic Sclerosis (dcSSc).